anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study aims at elucidating the mechanisms underlying the pathogenesis of diabetes. In particular, the study focusses on detailed analyses of morphological and functional properties of pancreatic islets/insulin-producing beta cells in order to identify diabetes-associated alterations on cellular and molecular levels. To directly address the role of the endocrine (and exocrine) pancreas in the complex process of diabetes development, the examinations are performed in samples of human pancreatic tissue. To this end, biopsy specimen of pancreas and visceral adipose tissue are collected from patients with or without diabetes who undergo (partial) pancreatectomy. The samples are analysed for morphological alterations (e.g. size and distribution of pancreatic islets and beta cells, size of adipocytes) and functional changes (e.g. gene expression patterns as assessed from beta-cell derived RNA). In addition, patient characteristics such as age and disease duration are documented and clinical data including fasting concentrations of blood glucose, insulin and free fatty acids are collected. Specific diabetes-associated alterations of pancreatic islet / beta cells are assessed by associating variables of glucose- and lipid-homeostasis with parameters of beta cell function. The expected outcomes of the study will contribute to improve our knowledge of the so far largely unknown molecular and cellular mechanisms involved in the pathogenesis of diabetes.
The control group will receive a glenohumeral arthroscopy, but no treatment concerning the subacromial structures. To allow for the best possible blinding, a 7-10 mm incision, mimicking the one used for ASAD, is performed on the lateral side of the arm 2-3 distal to the acromion. Participants are discharged with an arm sling and referred to 3 months physiotherapy in a municipally setting. Participants are given a rehabilitation program containing progressive exercises to guide the rehabilitation.
Eye movements (EM) during naming alphabetic versus logographic stimuli in children with and without developmental dyslexia (DD) were examined for each stimulus separately to identify conspicuous characteristics that influence naming performance. 40 children (group DD = 18; control group C = 22) were taught Chinese characters. EM were recorded during naming alphabetic words, pictures and Chinese characters. Main variables were articulation latencies, numbers and durations of fixations, secondary variables were fixation locations and error rates. Group DD showed significantly longer latencies and more fixations while reading words, but only insignificantly more fixations while naming pictures and Chinese characters. However, their error rate was significantly higher during naming Chinese characters but correlated neither with severity of phonological deficit nor with visual complexity. Their first fixation was significantly more often on the center of characters, in group C on the left. In both groups, EM variables were influenced by conspicuous features of characters, such as visual complexity, composition and structure. EM variables and scanning behavior while naming Chinese characters indicate holistic processing in the visuo-spatial pathway and were affected by conspicuous features of characters. The higher error rate in group DD could be determined by several factors, without a major role of the phonological deficit.
The invention discloses a xanthone compound as well as a preparation method and application of the xanthone compound. The xanthone compound has a structural formula shown in the specification, wherein R is -OH, a molecular formula of R is C17H1407, and the compound is named bracthone A; and R is -OMe, a molecular formula of R is C18H1607, and the compound is named bracthone B. The preparation method comprises the steps of: with branches, leaves and/or fruits ofdried garcinia arbor as raw materials, extracting extractum, carrying out extraction by using organic solvent, column chromatography on silica gels and high pressure liquid chromatography separation. The application refers to the application of the xanthone compound in preparation of anti-cancer drugs. The cytotoxic activity experiment shows that the bracthone A has high cytotoxic activity on NB4, A549 and PC3 cell strains; and the bracthone B has high cytotoxic activity on NB4, SHSY5Y, PC3 and MCF7. The xanthone compound has a simple structure, is good in activity, and be used as a guiding compound for anti-cancer drugs, and has good application prospect.
Disclosed are methods and products for epitope-directed immunization with a vaccine including an anti-idiotype antibody. The anti-idiotype antibody is conjutated to a carrier. The carrier is a protein against which the vaccine recipient has previously been immunized or otherwise previously exposed, or a peptide segment of such a protein containing determinants recognized by the antigen-specific receptors on the T helper cells, or an antibody which enhances the immune response against the anti-idiotype. The carrier should not alter the conformation of the anti-idiotype after conjugation. The anti-idiotype antibody is preferably one which induces production of neutralizing antibodies against HIV-1, in which case the preferred carrier is HBsAg or HIV-1 p24, or a T helper peptide derived from HBsAg or HIV-1 p24. It is more preferable if the anti-idiotype antibody induces production of neutralizing antibodies against the external envelope glycoprotein gp120 of HIV-1, and it is most preferable if it induces them against the principle neutralizing determinant of gp120. One such exemplary anti-idiotype antibody is AB19-4.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The clinical program for methylphenidate hydrochloride extended-release capsules consisted of 6 studies: 2 controlled clinical studies conducted in children with ADHD aged 6 to 12 years and 4 clinical pharmacology studies conducted in healthy adult volunteers. These studies included a total of 256 subjects; 195 children with ADHD and 61 healthy adult volunteers. The subjects received methylphenidate hydrochloride extended-release capsules in doses of 10 to 40 mg per day. Safety of methylphenidate hydrochloride extended-release capsules was assessed by evaluating frequency and nature of adverse events, routine laboratory tests, vital signs, and body weight. A placebo-controlled, double-blind, parallel-group study was conducted to evaluate the efficacy and safety of methylphenidate hydrochloride extended-release capsules in children with ADHD aged 6 to 12 years. All subjects received methylphenidate hydrochloride extended-release capsules for up to 4 weeks, and had their dose optimally adjusted, prior to entering the double-blind phase of the trial. In the 2-week double-blind treatment phase of this study, patients received either placebo or methylphenidate hydrochloride extended-release capsules at their individually-titrated dose (range, 10 mg to 40 mg).

Adverse reactions with an incidence greater than 5% during the initial 4-week single-blind methylphenidate hydrochloride extended-release capsules titration period of this study were headache, insomnia, upper abdominal pain, appetite decreased, and anorexia.

Adverse reactions with an incidence greater than 2% among methylphenidate hydrochloride extended-release capsules-treated subjects, during the 2-week double-blind phase of the clinical study, are shown in Table 2.

Table 2: Adverse Reactions in Greater Than 2% Methylphenidate Hydrochloride Extended-Release Capsules-Treated Subjects in the 2-Week Double-Blind Phase

Adverse Reactions Associated with Discontinuation of Treatment

In the 2-week double-blind treatment phase of a placebo-controlled parallel-group study in children with ADHD, one methylphenidate hydrochloride extended-release capsules-treated subject (1/65, 1.5%) discontinued due to an adverse event (depressed mood).

In the single-blind titration period of this study, subjects received methylphenidate hydrochloride extended-release capsules for up to 4 weeks. During this period a total of 6 subjects (6/161, 3.7%) discontinued due to adverse events. The adverse events leading to discontinuation were anger (2 patients), hypomania, anxiety, depressed mood, fatigue, migraine, and lethargy.
In one embodiment, the present invention provides a novel human PD1 isoform (Δ 42PD1) comprising a 42 nucleotide in-frame deletion in the exon 2 domain. Δ 42PD1 did not bind PD-L1/PD-L2 and could induce pro-inflammatory cytokine production. In one embodiment, Δ 42PD1 can be used as an intramolecular adjuvant to develop a method for enhancing antigen-specific CD8 + T cell immunity and fusion DNA vaccines for the prevention of pathogenic infections and/or cancer. In one embodiment, the soluble Δ 42PD1 protein may be a therapeutic target for autoimmune diseases. In other embodiments, a protein or peptide comprising Δ 42PD1 or a nucleic acid encoding a protein or peptide comprising Δ 42PD1 may be used as an immunogen for the development of antibodies that specifically bind Δ 42PD 1. In yet another embodiment, the neutralizing antibody can block Δ 42PD1 function and thus can be used as a treatment for autoimmune disorders.
In recent years, research has shown that oxidative stress plays a significant role in chronic inflammatory conditions. The alteration of the oxidant/antioxidant balance leads to the appearance of free radicals, important molecules involved in both diabetes mellitus and periodontal disease. Diabetes is considered to be one of the major risk factors of periodontal disease and the inflammation characterizing this condition is associated with oxidative stress, implicitly resulting in oxidative damage to DNA. 8-Hydroxydeoxyguanosine (8-OHdG) is the most common stable product of oxidative DNA damage caused by reactive oxygen species, and its levels have been reported to increase in body fluids and tissues during inflammatory conditions. 8-OHdG emerges as a pivotal biomarker for assessing oxidative DNA damage, demonstrating its relevance across diverse health conditions, including neurodegenerative disorders, cancers, inflammatory conditions, and periodontal disease. Continued research in this field is crucial for developing more precise treatments and understanding the detailed link between oxidative stress and the progression of periodontitis. The use of the 8-OHdG biomarker in assessing and managing chronic periodontitis is an area of increased interest in dental research, with the potential to provide crucial information for diagnosis and treatment.
The present invention provides compositions and methods for treating diseased, biological tissue; such as the epidermis or mucous membranes, in a mammal. Compositions of the present invention can be used to treat epidermal lesions, such as those resulting from viral and bacterial infections. In one embodiment, the present invention provides compositions useful for treating diseased, biological tissue, such as the epidermis or mucous membranes, in a mammal. The compositions of the present invention include at least one taxane. Preferably, the compositions of the present invention also include a natural oil, such as olive oil, and a wax, such as bees wax. In another embodiment, the present invention includes a method of treating diseased biological tissue, such as the epidermis or mucous membranes, in a mammal. The method of the present invention includes the step of contacting a diseased biological tissue, such as the epidermis, with a composition of the present invention containing an amount of a taxane, taxoid, or related compound, that is effective to ameliorate the disease symptoms.
Group of patients of any age, any sex, that will receive a complete scheme of approved Ad26.COV2 vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
MBT is conducted according to the treatment manual developed by Bateman \& Fonagy. Patients are offered weekly individual sessions with an MBT therapist for 12 months.
PURPOSE: A composition containing platycodin D for preventing and treating bone diseases is provided to reduce bone absorption and to suppress osteoclasia. CONSTITUTION: A composition for preventing or treating bone diseases contains platycodin D as an active ingredient. The platycodin D is contained in Platycodon grandiflorum extract. The Platycodon grandiflorum extract is obtained by isolating with water, butane, ethyl acetate, or mixture thereof. The bone diseases are bone injury, osteoporosis, richets, malacosteon, or metabolic bone diseases. A pharmaceutical composition for preventing and treating bone diseases contains therapeutically effective amount of the composition and pharmaceutically acceptable carrier.
BACKGROUND: Retinal ischemia-reperfusion (I/R) serves as a significant contributor to ocular diseases, triggering a cascade of pathological processes. The interplay between neuroinflammation and the apoptosis of retinal ganglion cell (RGC) is a well-explored aspect of retinal I/R-induced tissue damage. Within this intricate landscape, the inflammatory cytokine Interleukin-21 (IL21) emerges as a potent mediator of neuroinflammation with known detrimental effects on neuronal integrity. However, its specific impact on RGC apoptosis in the context of retinal I/R has remains to be uncovered. This study aims to unravel the potential anti-apoptotic effects of IL21 siRNA on RGC, shedding light on the neuroprotection of retinal I/R.
METHODS: Sprague-Dawley (SD) rats underwent a controlled elevation of intraocular pressure (IOP) to 110 mmHg for 60 min to simulate retinal I/R conditions. To explore the influence of IL21 on RGC apoptosis and its underlying molecular mechanisms, a comprehensive array of techniques such immunohistochemistry, immunofluorescence, TUNEL, Hematoxylin-eosin (H&E), immunoblotting, and qRT-PCR were carried out.
RESULTS: The landscape of retinal I/R injury revealed an increase in the expression of IL21, reaching its peak at 72 h. Notably, IL21 markedly induced RGC apoptosis within the retinal I/R milieu. The introduction of IL21 siRNA showed promising outcomes, manifesting as an amelioration of neurological function deficits, a reduction in RGC loss, and an increase in the thickness of the inner retinal layer at the 72-hour reperfusion. Additionally, IL21 siRNA demonstrated its ability to hinder the release of proteins associated with apoptosis via the JAK/STAT signaling pathway. In the in vitro setting, IL21 siRNA efficiently reduced R28 cell apoptosis by suppressing the production of proteins associated with apoptosis by regulating the JAK/STAT signaling pathway.
CONCLUSIONS: This study provides evidence for the pathogenic role of IL21 in retinal I/R. The findings underscore IL21 siRNA as a promising therapeutic target for ischemic retinal injury. Its efficacy lies in its ability to mitigate RGC apoptosis by suppressing the JAK/STAT signaling pathway. These findings not only enhance our comprehension of retinal I/R pathology but also suggests IL21 siRNA as a potential transformative factor in the development of targeted therapies for ischemic retinal injuries.
Participants in the control group will not have access to the FertiStrong app for the first 30 days. After a period of 30 days, participants will be provided downloading instructions to this app.
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. About 4 weeks after treatment, patients then undergo radical cystectomy per standard of care.
PURPOSE:To shorten a retrieving time and to maintain the picture quality together with reduction of the data quantity by providing a 1st picture store part which stores the picture data regardless of the types of pictures and a 2nd picture store part which stores selectively the specific picture data. CONSTITUTION:An input means 1b inputs the types of pictures (such as the names and the codes, etc., of the diagnositic departments, the doctors, the image pickup areas, the diseases, etc.). Many picture data SD received successively are stored in a 1st picture store part 2 regardless of the types of data SD. Mean while a 2nd picture store part 3 stores selectively only the data corresponding to the specific types out of those data SD. Therefore it is usually required to retrieve only the picture data stored in the part 3 for output of a desired picture. At the same time, the data quantity is extremely reduced with non-reversible compression and stored in the part 2. Then the data can be stored in the part 3 with the compression processing method varied in response to the retrieving frequency. Thus the data retrieving time is shortened and the picture quality is maintained together with reduction of the data quantity.
Participants (WL-RT) will be provided with a resistance exercise booklet containing instructions for exercises and links to demonstration videos. A demonstration and explanation of the exercises will be given at the beginning of the intervention, alongside a discussion of the principles of the programme such as starting level and progression. We will ask participants to perform the resistance exercises for 12-week period. Participants will be asked to perform exercises 3 times a week (3 sets reaching the RPE scale between 8 - 10 out of 10 (4-6 out of 10 in the first week)) for the intervention period. The exercises will include press-ups, band lateral raises, band seated low row, squat, lunge and calf raise.
Eight subjects with a probable MSA diagnosis will be recruited for this study. Each subject will undergo a \[F-18\]PBR06 PET scan at baseline, and at 9 months follow-up.
AIMS: The significance of micro-embolic signals (MESs) during atrial fibrillation (AF) ablation is unclear. Previous studies had limitations, and cryoballoon (CB) ablation patients were under-represented. Minimizing MESs is recommended due to their uncertain neurocognitive impact.
METHODS AND RESULTS: This prospective observational study included AF patients from a German centre between February 2021 and August 2022. Patients were equally divided into paroxysmal (Group A) and persistent (Group B) AF. Group A received cryoballoon-pulmonary vein isolation only, while Group B also had left atrial roof ablation. MESs were detected using transcranial Doppler ultrasonography during ablation. Neurocognitive status was assessed pre- and post-procedure and at 3 months using the CERAD Plus battery. The study analyzed 100 patients with a median age of 65.5 years. A total of 19 698 MESs were observed, with 80% being gaseous and 20% solid in origin, primarily occurring during pulmonary vein angiography and the balloon freeze and thawing phase. The median MES per patient was 130 (IQR: 92-256) in total, 298 (IQR: 177-413) in bilateral (36%), and 110 (IQR: 71-130) in unilateral (64%) recordings. No significant difference in total MES counts was found between the groups. None of the 11 neuropsychological tests showed cognitive decline post-procedure or at 3 months.
CONCLUSION: Our observations confirm that neurocognitive abilities are not affected either 24 h or 3 months after AF ablation using the CB technique. However, despite the low MES burden associated with the CB, more work is needed to reduce small embolic events during AF ablation.
Chronic inflammatory lesions (CIL) in the body are rare and inflammatory pseudotumor (IPT) is a subtype of CIL. Spine is an uncommon location of CIL, with most cases reported in the thoracic spine. Our objective was to review the current literature on IPT. To the best of our knowledge only about 13 cases are reported till date. A retrospective review of 13 existing cases was done. The etiopathogenesis of CIL is uncertain and total surgical excision remains the mainstay. It's a diagnosis of exclusion after ruling out commonly found lesions, both clinically and radiologically. Only histopathology can confirm the diagnosis. Total surgical resection remains the mainstay of treatment with adjuvant treatment only if there is a residue or a recurrence. CILs are rare lesions in the body with IPT being the commonest. Surgical excision remains the mainstay of treatment and a long-term follow up is warranted.
<P>PROBLEM TO BE SOLVED: To provide a method for detecting disease mutations (e.g. missense mutation, nonsense mutation, frame site mutation and splicing site mutation) of SCN2A in intractable childhood epilepsy accompanied by involution of critical mental faculties.  <P>SOLUTION: The present inventors found a nonsense mutation [monobasic mutation (c.304C→T)] producing R102X in a SCN2A gene of one patient of intractable symptomatic localization-related epilepsy accompanied by secondary generalized convulsive seizure among 77 patients diagnosed as severe myoclonic epilepsy of infancy (SMEI) or atypical SMEI. The present invention relates to SCN2A gene having disease mutation (e.g. missense mutation, nonsense mutation, frame shift mutation and splicing site mutation) and a primer and a probe for amplifying the gene. The invention further provides a method for detecting a mutation using the primer and the probe.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
FIELD: medicine. ^ SUBSTANCE: claimed invention related to novel substituted propanamide derivatives of general formula (I'), as well as their pharmaceutically acceptable salts and based on them pharmaceutical compositions, which possess suppressive activity against bone resorption and reduction of bone density, reducing concentration of calcium in blood. Claimed invention also relates to application of compounds of general formula (I') or their pharmaceutically acceptable salts and based on them pharmaceutical compositions for production of medications. Values m, n and R5-R9 substituents are given in invention formula. ^ EFFECT: invention results in methods of bone resorption suppression and reduction of bone mass, reduction of calcium concentration in blood, as well as to method of prevention and treatment of metabolic bone disease. ^ 28 cl, 4 tbl, 102 ex
Patients receive R-(-)-gossypol acetic acid PO QD on days 1-21. Beginning in course 2, patients also receive lenalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, and 15 of courses 2-12. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
PURPOSE:To recover interferon, in high yield, by contacting an interferon with an inorganic adsorbent in a highly concentrated salt solution, and eluting the adsorbed interferon with an eluent. CONSTITUTION:An interferon is made to contact with an inorganic adsorbent in a highly concentrated salt solution to effect the adsorption of the interferon to the adsorbent. The adsorbed interferon is eluted with an eluent. The interferon is, e.g. originated from interferon-producing microorganisms, human fibroblast cells, mouse cells, etc., and the salt in the solution is sulfate, chloride, phosphate, etc. The salt concentration is >=0.05M, preferably 0.5-1.5M. Too high concentration of the salt results in the precipitation of the interferon by salting out. The pH of the solution is 5-8, preferably 6.5-7.5.
Cross-sectional study of obese young adults who underwent PET/CT after cold exposure to identify active brown fat. No intervention. Enrolled 44 participants.
Participants will receive Ozanimod and work up to .92 mg. They will then take one pill daily for a duration of 12 months.
The dose of the CoronaVac vaccine will be 3 μg/0.5 mL. It will be administered by injection to the left deltoid muscle of the upper arm, two doses are given 28 days apart.